IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication

Journal of Clinical Oncology

Volumn 28, Issue 22, 2010, Pages 3636-3643

  Paschka, Peter ^a   Schlenk, Richard F ^a   Gaidzik, Verena I ^a   Habdank, Marianne ^a   Krönke, Jan ^a   Bullinger, Lars ^a   Späth, Daniela ^a   Kayser, Sabine ^a   Zucknick, Manuela ^a   Götze, Katharina ^a   Horst, Heinz A ^a   Germing, Ulrich ^a   Döhner, Hartmut ^a   Döhner, Konstanze ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

FLT3 LIGAND; ISOCITRATE DEHYDROGENASE; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE ISOENZYME; MIXED LINEAGE LEUKEMIA PROTEIN; NUCLEOPHOSMIN; UNCLASSIFIED DRUG; CD135 ANTIGEN; FLT3 PROTEIN, HUMAN; IDH1 PROTEIN, HUMAN; ISOCITRATE DEHYDROGENASE 2, HUMAN; NUCLEAR PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGE DISTRIBUTION; ARTICLE; AUSTRIA; CANCER SURVIVAL; CONTROLLED STUDY; CYTOGENETICS; FEMALE; FOLLOW UP; GENE DUPLICATION; GENE FREQUENCY; GENE MUTATION; GENETIC ASSOCIATION; GENOTYPE; GERMANY; HUMAN; INTERNAL TANDEM DUPLICATION; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RELAPSE FREE SURVIVAL; SUBSTITUTION REACTION; SURVIVAL TIME; TANDEM REPEAT; THROMBOCYTE; GENETICS; MIDDLE AGED; MORTALITY; MUTATION;

ADOLESCENT; ADULT; FEMALE; FMS-LIKE TYROSINE KINASE 3; HUMANS; ISOCITRATE DEHYDROGENASE; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MUTATION; NUCLEAR PROTEINS; PROGNOSIS; TANDEM REPEAT SEQUENCES;

EID: 77955907891     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.28.3762     Document Type: Article

References (47)

1. Mrózek K, Heerema NA, Bloomfield CD: Cytogenetics in acute leukemia. Blood Rev 18:115-136, 2004 (Pubitemid 38380667)
2. Grimwade D: The clinical significance of cytogenetic abnormalities in acute myeloid leukaemia. Best Pract Res Clin Haematol 14:497-529, 2001
3. Dö hner H, Estey EH, Amadori S, et al: Diagnosis and management of acute myeloid leukemia in adults: Recommendations from an international expert panel, on behalf of the European Leukemia-Net. Blood 115:453-474, 2010
4. Haselbeck RJ, McAlister-Henn L: Function and expression of yeast mitochondrial NAD- and NADP-specific isocitrate dehydrogenases. J Biol Chem 268:12116-12122, 1993 (Pubitemid 23168178)
5. Plaut GW, Cook M, Aogaichi T: The subcellular location of isozymes of NADP-isocitrate dehydrogenase in tissues from pig, ox and rat. Biochim Biophys Acta 760:300-308, 1983
6. Narahara K, Kimura S, Kikkawa K, et al: Probable assignment of soluble isocitrate dehydrogenase (IDH1) to 2q33.3. Hum Genet 71:37-40, 1985 (Pubitemid 16252285)
7. Geisbrecht BV, Gould SJ: The human PICD gene encodes a cytoplasmic and peroxisomal NADP(+)-dependent isocitrate dehydrogenase. J Biol Chem 274:30527-30533, 1999
8. Oh IU, Inazawa J, Kim YO, et al: Assignment of the human mitochondrial NADP(+)-specific isocitrate dehydrogenase (IDH2) gene to 15q26.1 by in situ hybridization. Genomics 38:104-106, 1996 (Pubitemid 26423924)
9. Jo SH, Son MK, Koh HJ, et al: Control of mitochondrial redox balance and cellular defense against oxidative damage by mitochondrial NADP+-dependent isocitrate dehydrogenase. J Biol Chem 276:16168-16176, 2001
10. Lee SH, Jo SH, Lee SM, et al: Role of NADP+-dependent isocitrate dehydrogenase (NADP+-ICDH) on cellular defence against oxidative injury by gammarays. Int J Radiat Biol 80:635-642, 2004
11. Koh HJ, Lee SM, Son BG, et al: Cytosolic NADP+-dependent isocitrate dehydrogenase plays a key role in lipid metabolism. J Biol Chem 279: 39968-39974, 2004
12. Sjöblom T, Jones S, Wood LD, et al: The consensus coding sequences of human breast and colorectal cancers. Science 314:268-274, 2006 (Pubitemid 44571966)
13. Parsons DW, Jones S, Zhang X, et al: An integrated genomic analysis of human glioblastoma multiforme. Science 321:1807-1812, 2008
14. Yan H, Parsons DW, Jin G, et al: IDH1 and IDH2 mutations in gliomas. N Engl J Med 360:765-773, 2009
15. Balss J, Meyer J, Mueller W, et al: Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol 116:597-602, 2008
16. Bleeker FE, Lamba S, Leenstra S, et al: IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors. Hum Mutat 30:7-11, 2009
17. Ichimura K, Pearson DM, Kocialkowski S, et al: IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro Oncol 11:341-347, 2009
18. Kang MR, Kim MS, Oh JE, et al: Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers. Int J Cancer 125:353-355, 2009
19. Watanabe T, Nobusawa S, Kleihues P, et al: IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol 174:1149-1153, 2009
20. Hartmann C, Meyer J, Balss J, et al: Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: A study of 1,010 diffuse gliomas. Acta Neuropathol 118:469-474, 2009
21. Hayden JT, Frü hwald MC, Hasselblatt M, et al: Frequent IDH1 mutations in supratentorial primitive neuroectodermal tumors (sPNET) of adults but not children. Cell Cycle 8:1806-1807, 2009
22. Sanson M, Marie Y, Paris S, et al: Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol 27:4150-4154, 2009
23. Park SW, Chung NG, Han JY, et al: Absence of IDH2 codon 172 mutation in common human cancers. Int J Cancer 125:2485-2486, 2009
24. Mardis ER, Ding L, Dooling DJ, et al: Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 361:1058-1066, 2009
25. Gaal J, Burnichon N, Korpershoek E, et al: Isocitrate dehydrogenase mutations are rare in pheochromocytomas and paragangliomas. J Clin Endocrinol Metab 95:1274-1278, 2010
26. Watanabe T, Vital A, Nobusawa S, et al: Selective acquisition of IDH1 R132C mutations in astrocytomas associated with Li-Fraumeni syndrome. Acta Neuropathol 117:653-656, 2009
27. Schlenk RF, Dö hner K, Pralle H, et al: Risk-adapted therapy in younger adults with acute myeloid leukemia: Results of the AMLHD98A trial of the AMLSG. Blood 108:8a, 2006 (abstr 14)
28. Schlenk RF, Germing U, Hartmann F, et al: High-dose cytarabine and mitoxantrone in consolidation therapy for acute promyelocytic leukemia. Leukemia 19:978-983, 2005 (Pubitemid 40862008)
29. Schlenk RF, Dö hner K, Krauter J, et al: Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 358: 1909-1918, 2008
30. Frueh FW, Noyer-Weidner M: The use of denaturing high-performance liquid chromatography (DHPLC) for the analysis of genetic variations: Impact for diagnostics and pharmacogenetics. Clin Chem Lab Med 41:452-461, 2003 (Pubitemid 36592108)
31. Korn EL: Censoring distributions as a measure of follow-up in survival analysis. Stat Med 5:255-260, 1986
32. Cheson BD, Bennett JM, Kopecky KJ, et al: Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 21:4642-4649, 2003 (Pubitemid 46594039)
33. Kaplan E, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
34. Therneau TM, Grambusch PM: Modeling Survival Data: Extending the Cox Model. New York, NY, Springer Verlag, 2000
35. Cox DR: Regression models and life tables (with discussion). J R Stat Soc B 34:187-220, 1972
36. Grambsch PM, Therneau TM: Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 81:515-526, 1994
37. Harrell FE: Regression modeling strategies: With applications to linear models, logistic regression, and survival analysis. New York, NY, Springer Verlag, 2001
38. R Development Core Team R: A Language and Environment for Statistical Computing. Vienna, Austria, R Foundation for Statistical Computing, 2007
39. Schnittger S, Haferlach C, Ulke M, et al: IDH1 mutations are detected in 9.3% of all AML and are strongly associated with intermediate risk karyotype and unfavourable prognosis: A study of 999 patients. Presented at 51st Meeting of the American Society of Hematology, New Orleans, LA, December 5-8, 2009
40. Nekrutenko A, Hillis DM, Patton JC, et al: Cytosolic isocitrate dehydrogenase in humans, mice, and voles and phylogenetic analysis of the enzyme family. Mol Biol Evol 15:1674-1684, 1998 (Pubitemid 28550991)
41. Xu X, Zhao J, Xu Z, et al: Structures of human cytosolic NADP-dependent isocitrate dehydrogenase reveal a novel self-regulatory mechanism of activity. J Biol Chem 279:33946-33957, 2004 (Pubitemid 39063045)
42. Zhao S, Lin Y, Xu W, et al: Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science 324:261-265, 2009
43. Dang L, White DW, Gross S, et al: Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462:739-744, 2009
44. Struys EA, Salomons GS, Achouri Y, et al: Mutations in the D-2-hydroxyglutarate dehydrogenase gene cause D-2-hydroxyglutaric aciduria. Am J Hum Genet 76:358-360, 2005 (Pubitemid 40129562)
45. Van Schaftingen E, Rzem R, Veiga-da-Cunha M: L-2-hydroxyglutaric aciduria: A disorder of metabolite repair. J Inherit Metab Dis 32:135-142, 2009
46. Yazici N, Sarialioǧlu F, Alkan O, et al: L-2-hydroxyglutaric aciduria and brain tumors: A case report and review of the literature. J Pediatr Hematol Oncol 31:865-869, 2009
47. Moroni I, Bugiani M, D'Incerti L, et al: L-2-hydroxyglutaric aciduria and brain malignant tumors: A predisposing condition? Neurology 62:1882-1884, 2004